(Q36461600)

14 August 2017

1 reference

title

The IgA nephropathy treatment dilemma (English)

1 reference

14 August 2017

1 reference

Appel GB

1

1 reference

14 August 2017

Waldman M

series ordinal

2

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 June 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

69

1 reference

14 August 2017

issue

11

1 reference

14 August 2017

page(s)

1939-1944

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.ki.5000434

14 August 2017

exact match

0 references

cites work

Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000434

7 January 2021

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000434

7 January 2021

Fibroblast-specific protein 1 is a specific prognostic marker for renal survival in patients with IgAN.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000434

7 January 2021

Predicting progression in IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000434

7 January 2021

Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000434

7 January 2021

Uric acid correlates with the severity of histopathological parameters in IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000434

7 January 2021

Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin a nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000434

7 January 2021

Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000434

7 January 2021

Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000434

7 January 2021

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000434

7 January 2021

Effect of lipid reduction on the progression of renal disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000434

7 January 2021

A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000434

7 January 2021

Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000434

7 January 2021

The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000434

7 January 2021

The role of fish oil/omega-3 fatty acids in the treatment of IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000434

7 January 2021

Eicosapentaenoic acid and IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000434

7 January 2021

A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000434

7 January 2021

Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000434

7 January 2021

Corticosteroids in IgA nephropathy: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000434

7 January 2021

Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000434

7 January 2021

Immunosuppressive treatments for immunoglobulin A nephropathy: a meta-analysis of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000434

7 January 2021

Prednisolone and azathioprine in IgA nephropathy - a ten-year follow-up study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000434

7 January 2021

Clinical presentation, natural history, and treatment of crescentic proliferative IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000434

7 January 2021

Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000434

7 January 2021

Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000434

7 January 2021

Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000434

7 January 2021

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000434

7 January 2021

Identifiers

DOI

10.1038/SJ.KI.5000434

1 reference

Dimensions Publication ID

14 August 2017

1031195215

0 references

1 reference